Every material Form 8-K EyePoint, Inc. has filed with the SEC since September 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
EyePoint said its Phase 3 LUCIA trial of DURAVYU in wet AMD did not meet its primary non-inferiority endpoint, and its board approved a plan to reduce operating expenses and focus on diabetic macular edema (DME). The plan cuts the workforce by about 53%, concludes the pivotal wet AMD trials early, and carries about $9 million in employee separation charges, which shareholders would bear as a cost.
The LUCIA wet AMD trial did not meet its primary endpoint of non-inferiority, though it met key secondary endpoints, per the press release.
Approximately 53% of positions are affected, with most of the reduction expected in Q4 2026 and completion in the first half of 2027.
Estimated aggregate employee separation charges are about $9 million, and annualized savings are estimated at about $30 million.
Cash, cash equivalents and short-term investments were about $118 million as of September 30, 2026, a preliminary, unaudited figure; pivotal DME Phase 3 topline data is expected in Q4 2027.
EyePoint reported topline results from LUCIA, the second pivotal Phase 3 trial of DURAVYU in wet AMD, which did not meet its primary endpoint of statistical non-inferiority in mean change in best-corrected visual acuity versus on-label aflibercept. The company said several key secondary endpoints were met, and it will run additional analyses of LUCIA and the pooled Phase 3 data to assess next steps for wet AMD, while the DME program continues.
LUCIA did not meet its primary endpoint; the presentation shows a mean BCVA change of +2.5 letters for DURAVYU versus +6.1 letters for aflibercept, a difference of -3.7 letters (preliminary data).
LUCIA enrolled 475 patients; DURAVYU achieved a 38% reduction in treatment burden (nominal p-value below 0.0001) and 52% of eyes were supplement-free up to Week 56.
EyePoint will complete additional analyses of LUCIA and the pooled Phase 3 datasets to assess next steps for DURAVYU in wet AMD.
Pivotal Phase 3 DME topline data are anticipated in the fourth quarter of 2027.
EyePoint posted an updated investor presentation on September 10, 2026, with preliminary topline results from the LUGANO Phase 3 wet AMD trial of DURAVYU. The filing states DURAVYU did not achieve statistical non-inferiority to on-label aflibercept in the full data set, a miss on the primary endpoint, and the company attributes the result mainly to 9 patients who lost 15 or more letters of vision from non-wet AMD causes.
Full data set: DURAVYU did not achieve statistical non-inferiority on mean change in BCVA versus on-label aflibercept (preliminary, pending final analysis).
Excluding the 9 of 211 DURAVYU patients in the asymmetric cohort, non-inferiority was achieved (nominal p=0.0096).
LUCIA Phase 3 data are expected in Q4 2026, and a wet AMD NDA filing is targeted for 1H 2027.
The presentation is filed as Exhibit 99.1 and is incorporated by reference; all LUGANO data are labeled preliminary.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every EyePoint, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →